Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Are Wall Street Analysts Bullish on Bio-Techne Stock?

May 25, 2026 at 14:23 PM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

With a market cap of $7.5 billion, Bio-Techne Corporation (TECH) is a global life sciences company that develops, manufactures, and sells reagents, instruments, and services for research, diagnostics, and bioprocessing applications. It operates through its Protein Sciences and Diagnostics and Spatial Biology segments, providing innovative solutions for life science research, cell and gene therapy, molecular diagnostics, and spatial biology.

Shares of Bio-Techne have lagged behind the broader market over the past 52 weeks. HCA stock has risen 1.9% over this time frame, while the broader S&P 500 Index ($SPX) has gained 27.9%. In addition, the stock has declined 18% on a YTD basis, compared to SPX's 9.2% return.

More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.

Looking closer, shares of the Minneapolis, Minnesota-based company have underperformed the State Street Health Care Select Sector SPDR ETF's (XLV) 14.8% increase over the past 52 weeks.

Shares of Bio-Techne tumbled 16.4% on May 6 after the company reported weaker-than-expected Q3 2026 results, with revenue declining 2% year-over-year to $311.4 million and adjusted EPS falling to $0.53, as softer biotech spending continued to offset strong demand from large pharmaceutical customers. Investors were particularly concerned that organic revenue also declined 2%, driven by lower GMP fast-track orders, delayed large Commercial Supply shipments, and continued weak purchasing activity from emerging biotech clients despite an improving biotech funding environment.

For the fiscal year ending in June 2026, analysts expect TECH’s EPS to dip 1.2% year-over-year to $1.69. However, the company's earnings surprise history is promising. It beat or met the consensus estimates in the last four quarters.

Among the 15 analysts covering the stock, the consensus rating is a “Moderate Buy.” That’s based on nine “Strong Buy” ratings, one “Moderate Buy,” and five “Holds.”

On May 7, Wells Fargo analyst Brandon Couillard lowered the price target for Bio-Techne to $62 while maintaining an “Overweight” rating.

The mean price target of $63.75 represents a 32.2% premium to TECH’s current price levels. The Street-high price target of $80 suggests a 65.9% potential upside.

On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

More news from Barchart

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article